Floatz logo

Daunorubicin

Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation

National Cancer Institute (NCI)Phase 3Dormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Alice Mims
Phase 3BBB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 3BBB
Idarubicine
The First Affiliated Hospital of Soochow University
Phase 2BBB
Mitoxantrone
BGI, China
Phase 2BBB
Cyclophosphamide
BGI, China
Phase 3BBB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →